Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-026-04906-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Md Arif Ansari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India. Hauptthemen laut MEDLINE: Immunoconjugates, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manipal Academy of Higher Education, Manipal.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, largely because of tumor heterogeneity, therapeutic resistance, and the limited efficacy of existing targeted therapies in advanced disease. Antibody-drug conjugates (ADCs) have emerged as a promising class of targeted anticancer therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of highly active payloads, thereby enabling selective tumor cell killing while minimizing systemic toxicity. Although ADCs have demonstrated substantial clinical success in several solid and hematological malignancies, their translation to CRC has been relatively limited, underscoring the need for a focused evaluation of CRC-specific ADC development. This review provides a comprehensive and critical overview of recent advances in ADC design and preclinical development for CRC, with emphasis on molecular architecture, linker-payload chemistry, antigen selection, and pharmacological mechanisms of action. Key components of ADCs, including antibody formats, cleavable and noncleavable linkers, and cytotoxic payload classes such as auristatins, maytansinoids, duocarmycins, and topoisomerase inhibitors, are discussed in the context of optimizing the therapeutic index and tumor selectivity. Mechanistic aspects of ADC activity, including antigen-mediated internalization, intracellular trafficking, payload release, and the bystander effect, are highlighted for their relevance to heterogeneous CRC tumors. This review systematically summarizes emerging preclinical ADC candidates targeting CRC-associated antigens, including EGFR, CEACAM5, c-Met, RON, DDR1, GPR56, LGR5, Claudin-2, and CD98hc. Finally, key translational challenges-including antigen heterogeneity, limited internalization, and off-target toxicity-are discussed alongside future perspectives emphasizing biomarker-driven patient selection and rational ADC design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, 844102, India.
- Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411008, Maharashtra, India.
- Department of Pharmaceutics, Deccan School of Pharmacy, Darussalam, Aghapura, Nampally, Hyderabad, 500 001, Telangana, India.
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, 844102, India.
- Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, 844102, India.
Förderung
- Manipal Academy of Higher Education, Manipal
Zitieren
APA
Ansari, M. A., Abubakar, M., Ansari, M. M., Koya, N., Gupta, J., Aazam, M., Shinde, S. S., Ahmed, S., Rai, A., Murti, K., Pal, B., Rai, S. N., Kaur, P., Shenoy, S., & Kumar, N. (2026). Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04906-9
Vancouver
Ansari MA, Abubakar M, Ansari MM, Koya N, Gupta J, Aazam M, et al. Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04906-9
BibTeX
@article{Ansari2026,
author = {Ansari, Md Arif and Abubakar, Md and Ansari, Mohd Mazharuddin and Koya, Nabeeha and Gupta, Janmejay and Aazam, Maria and Shinde, Sonali Sandeep and Ahmed, Sana and Rai, Amita and Murti, Krishna and Pal, Biplab and Rai, Sachchida Nand and Kaur, Palwinder and Shenoy, Smita and Kumar, Nitesh},
title = {Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-026-04906-9}
}
EUVIMED